ACXP News & Events

The Company ended the quarter with cash totaling $5.9M, compared to $3.7M as of December 31, 2024. During the Q3, the Company raised a total of approximately $1.7M of gross proceeds through purchases under the Equity Line of Credit. In addition, after quarter end, the Company raised an additional $1.4M from a warrant exercise by one institutional investor.

Acurx Pharmaceuticals announced the publication of results from its scientific collaboration with Leiden University Medical Center, or LUMC, demonstrating structural biology research that reveals for the first time a DNA pol IIIC inhibitor, ibezapolstat, bound to its target. The publication is entitled: A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens. The senior author is Wiep Klaas Smits, Associate Professor and Principal Investigator for Pol C Inhibitors, Leiden University Medical Center, Netherlands. According to Smits: "Results of this work provide mechanistic insights into ibezapolstat's mode-of-action and a structural explanation for its selective antibacterial spectrum". He added: "Advancement of small-molecule PolC inhibitors, a new-to-nature class of compounds, will be facilitated by these new insights into the structural determinants for inhibition laying the foundation for the rational development of an innovative class of antimicrobials against Gram-positive priority pathogens."

Acurx Pharmaceuticals announced that a new patent has been granted by the Australian Patent Office. This patent relates to DNA Polymerase IIIC Inhibitors, including compositions-of- matter. This is the latest in the series of granted patents and pending patent applications that Acurx has filed to protect its proprietary technologies in the field of antimicrobials. To date, Acurx has obtained three U.S. patents, one Israeli patent, one Japanese patent, one Indian patent, and now an Australian patent, in each case, which cover the ACX-375C program, relating to DNA Polymerase IIIC Inhibitors, with other country-level filings in process.